Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

Sponsored by Emory University

Phase Quota
Phase 2

The purpose of the study is to find out if trastuzumab alone or trastuzumab in combination with everolimus is effective in metastatic breast cancers that are no longer controlled by hormonal therapies.

Study Start Date: May 2009

Estimated Completion Date: October 2016

Specialties: Obstetrics & Gynecology: Breast,Clinical Pharmacology Oncology: Breast,Pharmacology/Therapy Pharmacy: Chemotherapy/Oncology Physician Assistant: Clinical Pharmacology,Hematology/Oncology


  • Biological: Trastuzumab
  • Drug: Everolimus
  • Drug: Trastuzumab (Herceptin) plus Everolimus
  • Drug: Trastuzumab (Herceptin)

Inclusion criteria

  • Patients will be included in the study based on the following criteria:
    • Hormone-refractory metastatic breast cancer defined as disease progression within 6 months from starting most recent hormonal therapy
    • At least 2 prior endocrine therapies, including in the adjuvant setting. Patients must have had at least one hormonal agent in the metastatic setting
    • Candidate for hormonal therapy (ER and/or PR-positive at primary diagnosis and at metastatic diagnosis where tissue is available)
    • HER2/neu-negative breast cancer by standard criteria (FISH-negative and IHC <3+) at primary diagnosis
    • If biopsy of metastatic lesion is performed prior to study entry, HER2 expression by IHC must be 1+ or 2+
    • Histologically confirmed, measurable disease
    • Life expectancy > 6 months
    • Age >18 years
    • ECOG performance status
    • Adequate bone marrow function as indicated by the following:
    • ANC >1500/uL Platelets >=100,000/uL Hemoglobin >10 g/dL
    • Adequate renal function, as indicated by creatinine <=1.5x upper limit of normal (ULN)
    • Adequate liver function, as indicated by bilirubin <=1.5x ULN
    • INR <= 1.3 (or <= 3 on anticoagulants)
    • AST or ALT <2x ULN unless related to primary disease
    • Signed informed consent
    • Adequate birth control
    • Fasting serum cholesterol <=300 mg/dL OR <=7.75 mmol/L AND fasting triglycerides <= 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication

Exclusion criteria

  • Patients will be excluded from the study based on the following criteria:
    • Prior treatment with trastuzumab or other HER2-directed therapies or with an mTOR inhibitor (25)
    • HER2 0 or 3+ by IHC on pre-treatment biopsy of metastatic lesion (if performed)
    • Active infection
    • Uncontrolled central nervous system metastases
    • Pregnant or lactating women
    • Prior chemotherapy within the last 4 weeks
    • Prior radiation therapy within the last 4 weeks; prior radiation therapy to indicator lesion (unless objective disease recurrence or progression within the radiation portal has been documented since completion of radiation)
    • Concomitant malignancies or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
    • History of significant cardiac disease, cardiac risk factors or uncontrolled arrhythmias
    • Ejection fraction <50% or below the lower limit of the institutional normal range, whichever is lower
    • Hypersensitivity to trial medications
    • Emotional limitations
    • Prior treatment with any investigational drug within the preceding 4 weeks Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent
    • Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
    • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
    • A known history of HIV seropositivity
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
    • Patients with an active, bleeding diathesis
    • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)
    • Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)
    • Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs, resulting in dyspnea at rest
    • Taking any of the following agents:
    • Chronic treatment with systemic steroids or another immunosuppressive agent
    • Live vaccines
    • Drugs or substances known to be inhibitors or inducers of the isoenzyme CYP3A

Study Locations And Contact Information

  • Emory University Winship Cancer Institute, Atlanta Georgia
    Contact: Regina Mosley 404-778-4824
  • Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago Illinois
    Contact: Leeaht Gross
  • Emory University Hospital Midtown, Atlanta Georgia
    Contact: Regina Mosley 404-778-4824

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.